Your browser doesn't support javascript.
Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid, Robert L; Black, Denise; Derzko, Christine; Portman, David.
  • Reid RL; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Queen's University, Kingston, ON. Electronic address: robert.reid@queensu.ca.
  • Black D; Department of Obstetrics, Gynecology and Reproductive Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB.
  • Derzko C; Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON; Department of Internal Medicine (Endocrinology), University of Toronto, Toronto, ON.
  • Portman D; Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH.
J Obstet Gynaecol Can ; 42(3): 301-303, 2020 Mar.
Article in English | MEDLINE | ID: covidwho-1291550
Semantic information from SemMedBD (by NLM)
1. novel AODU treatment method TREATS Vulvovaginal atrophy
Subject
novel AODU treatment method
Predicate
TREATS
Object
Vulvovaginal atrophy
2. estrogens ADMINISTERED_TO Partner
Subject
estrogens
Predicate
ADMINISTERED_TO
Object
Partner
3. Body tissue PART_OF Vagina
Subject
Body tissue
Predicate
PART_OF
Object
Vagina
4. Body tissue LOCATION_OF Estrogenic
Subject
Body tissue
Predicate
LOCATION_OF
Object
Estrogenic
5. novel AODU treatment method TREATS Vulvovaginal atrophy
Subject
novel AODU treatment method
Predicate
TREATS
Object
Vulvovaginal atrophy
6. estrogens ADMINISTERED_TO Partner
Subject
estrogens
Predicate
ADMINISTERED_TO
Object
Partner
7. Body tissue PART_OF Vagina
Subject
Body tissue
Predicate
PART_OF
Object
Vagina
8. Body tissue LOCATION_OF Estrogenic
Subject
Body tissue
Predicate
LOCATION_OF
Object
Estrogenic
ABSTRACT
Vulvovaginal atrophy (VVA) resulting from estrogen deprivation at menopause often results in distressing vaginal dryness and dyspareunia. Fewer than 25% of affected women seek help for this condition citing embarrassment, cultural values, an aging or unavailable partner and concerns about use of estrogens following the Women's Health Initiative. Available non-hormonal treatments, such as moisturizers, while affording some relief can be messy to apply and do not prevent disease progression. A new oral selective estrogen receptor modulator, ospemifene, has been found to have strong estrogenic activity in vaginal tissues without adverse estrogenic effects at other sites.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Atrophy / Tamoxifen / Vagina / Vulva / Menopause / Selective Estrogen Receptor Modulators Limits: Aged / Female / Humans / Middle aged Language: English Journal: J Obstet Gynaecol Can Journal subject: Gynecology / Obstetrics Year: 2020 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: Atrophy / Tamoxifen / Vagina / Vulva / Menopause / Selective Estrogen Receptor Modulators Limits: Aged / Female / Humans / Middle aged Language: English Journal: J Obstet Gynaecol Can Journal subject: Gynecology / Obstetrics Year: 2020 Document Type: Article